uniQure N.V. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter ended September 30, 2026, and reporting total assets of $940.6 million on its unaudited consolidated balance sheet.
Key Highlights
- Total assets of $940.6 million as of September 30, 2026, up from $824.9 million as of December 31, 2025, according to the filing.
- Cash and cash equivalents of $98.4 million as of September 30, 2026, compared with $80.2 million at December 31, 2025.
- Current investment securities of $570.0 million and non-current investment securities of $100.0 million as of September 30, 2026; no non-current investment securities were reported at December 31, 2025.
- 70,138,860 ordinary shares outstanding as of November 2, 2026, each with a par value of €0.05, as the registrant disclosed.
- Intangible assets, net of $61.9 million as of September 30, 2026, down from $72.8 million at December 31, 2025, the filing shows.
- Biologics License Application for ifezuntirgene inilparvovec (also referred to as AMT-130) to the FDA was cited among key forward-looking matters subject to the company's cautionary language.
uniQure's Balance Sheet and Financial Position for the September 30, 2026 Quarter
According to the filing, uniQure N.V. (NASDAQ:QURE), incorporated in the Netherlands, reported total current assets of $692.5 million as of September 30, 2026, rising from $656.0 million at December 31, 2025. The increase was driven in part by growth in current investment securities, which reached $570.0 million compared with $542.3 million at year-end 2025, and by higher cash and cash equivalents of $98.4 million versus $80.2 million.
The company's non-current assets grew to $248.0 million from $168.9 million at December 31, 2025, the filing disclosed. A notable change was the appearance of non-current investment securities of $100.0 million, which carried a zero balance at December 31, 2025. Property, plant and equipment, net declined to $9.9 million from $13.8 million, and goodwill stood at $24.5 million as of September 30, 2026, compared with $25.4 million at year-end. Prepaid expenses fell to $9.6 million from $20.5 million. On the liabilities side, accrued expenses and other current liabilities increased to $51.0 million from $41.3 million, and accounts payable rose to $6.2 million from $5.2 million, according to the filing.
The filing noted that the company is pursuing a Biologics License Application for ifezuntirgene inilparvovec with the FDA and a Marketing Authorisation Application with the United Kingdom's Medicines and Healthcare products Regulatory Agency. The filing also stated plans to conduct a confirmatory study for ifezuntirgene inilparvovec. These statements are described by the company as forward-looking and are subject to the cautionary language included in the quarterly report. The registrant is classified as a large accelerated filer and is not a shell company.
What Was Disclosed
uniQure N.V. filed a Form 10-Q for the quarter ended September 30, 2026, disclosing an unaudited consolidated balance sheet showing total assets of $940.6 million and 70,138,860 ordinary shares outstanding as of November 2, 2026.




Please wait processing your request...